Flaskdata Announces Partner Program With Promedoss

Modiin, Israel based Flaskdata.io is pleased to announce the launch of a partnership with Triangle Park, North Carolina based Promedoss. Flaskdata.io is an Israeli tech startup that specializes in helping life sciences companies complete their Phase 2 and Phase 3 clinical trials 3-6 months faster. Promedoss offers a wide and unique range of services that go beyond clinical trial operations. Their specialities include funding, business development, regulatory compliance, quality management, risk management, operations, marketing strategy and reimbursements.

Danny Lieberman, CEO of Flaskdata.io, says, “We are very pleased to announce our partnership with Promedoss, one of the leading companies in North Carolina that specializes in working with early stage medical device companies. They have been a source of valuable insight to us and to two of our most important customers—Vibrant Gastro and Dario Health.”

He adds, “Flaskdata recognizes that patient compliance is the single most critical obstruction to the success of patient-centric studies, decentralised trials, site-less trials, digital therapeutics and home-use devices. With the Flaskdata partner program, Flaskdata and Promedoss work hand-in-hand to help Israeli medical device startups as well as ensure that young entrepreneurs bring medical devices to market in a fast, efficient and highly cost-effective manner.”

Flaskdata.io is a cloud platform used for the real-time collection of clinical data as well as AI-driven detection and response to protocol compliance issues. As stated on the company’s website, responding promptly to such issues is critical and has significant implications in terms of the budget as well as the timeline of any clinical study. The company asserts that the automated detection of these protocol compliance issues can significantly decrease the associated costs, and their platform can notify those concerned on deviations over 100 times faster compared to the present manual methods of risk-based monitoring and central monitoring services. By catching these issues in a timely manner and allowing for speedy corrective action through AI-detection, the sponsor and CRO can keep the study on track and minimize DM queries.

Lieberman also explains that the Flaskdata.io platform provides an immediate real-time depiction of the compliance posture of a study at any level of granularity of time, subject or site. This is accomplished through the Detect & Respond subsystem as it processes the continuous data feed. The Flaskdata.io automation platform helps life sciences companies obtain interpretable data in near-real time and can shorten clinical trial completion times between three and six months.

As part of their wide ranging utilization of technology, Flaskdata.io has a patient engagement application that can run on desktop computers and mobile devices. This application, called Flask forms, allows Flaskdata’s clients to create an application to be used for patient engagement automation. This can be completed easily in a matter of minutes using a friendly drag and drop user interface.

Flaskdata.io takes pride in their ability to collect data from any combination of sources, including investigators, patients, mobile, wearables, passive monitoring, connected medical devices and codes. The platform is HIPAA, GDPR and 21 CFR Part 11 compliant. Additionally, it integrates EDC, mobile ePRO and connected devices using a continuous data feed. The Flaskdata.io platform currently supports studies at over 350 investigational sites in Europe, United States and Israel. The company works with life science sponsors and CROs to design, implement and operate patient-centric clinical trials. It integrates continuous data feeds from patients, investigators and connected devices with automated detection and response to protocol violations in real-time.

Additionally, the Flaskdata.io ‘Powered by Flask’ program offers digital therapeutics, digital health and medtech developers free and open access to the Flask API. It also offer them the ability to stream and retrieve clinical data from the platform, through the Flaskdata Digital Ingest System, from any and all data sources in the client’s digital study (at a rate of over 100,000 events per second). This reduces their time-to-market for HIPAA and GDPR-compliant patient management solutions.

Finally, Flaskdata asserts that their technology runs on high performance, secure cloud instances and integrates with EDC and ePRO using the Flask API service. Clinical trial data is stored in secure cloud instances and is protected by strong access control and extended SSL transmission security and a team dedicated to data security.

Contact details are available on the company’s website. Interested parties may also connect with Flaskdata.io via social media to stay abreast of their latest news and important announcements. Get in touch with the company here: Contact For More Information.